v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 11,707 $ 13,012
General and administrative 3,908 3,988
Total operating expenses 15,615 17,000
Loss from operations (15,615) (17,000)
Other income:    
Interest income 458 1,075
Total other income 458 1,075
Net loss and comprehensive loss $ (15,157) $ (15,925)
Net loss per share attributable to common stockholders, basic $ (1.11) $ (1.19)
Net loss per share attributable to common stockholders, diluted $ (1.11) $ (1.19)
Weighted average shares outstanding: basic 13,674,577 13,424,335
Weighted average shares outstanding: diluted 13,674,577 13,424,335